New Breast Cancer Staging System Incorporates HER2 Status to Better Assess Prognosis
From - Diagnostic Testing & Emerging Technologies A new breast cancer staging system adds HER2 (ERBB2-positive disease) status to a list of factors used to assess prognosis in women who undergo neoadjuvant (pre-surgical) therapy for… . . . read more

Subscribe to Clinical Diagnostics Insider to view
Start a Free Trial for immediate access to this article